Regular physical activity is an integral part of the life of patients with type 1 diabetes mellitus (DM1) due to their young age. Regular aerobic physical activity is associated with improved overall well-being and is a method of preventing cardiovascular diseases. An increased risk of nocturnal hypoglycemia after physical activity is a factor limiting physical activity, especially in young patients and children. Insulin degludec is an analogue of long-acting basal insulin (with a duration of action of more than 42 hours), which has a low variability of action. The ADREM study, conducted using continuous glucose monitoring systems, demonstrated that afternoon aerobic exercise in patients with DM1 treated with insulin degludec did not affect the risk of subsequent nocturnal hypoglycemia. This article reviews a case series of patients with DM1 treated with insulin degludec and regularly engaged in physical activity.

Keywords: degludec, basal insulin analogue, glycemic variability, diabetes mellitus, exercise